At the World Cancer Congress (WCC) in Switzerland, researchers presented evidence linking exposure to proton pump inhibitors (PPIs) with an increased risk for certain cancers.
The Congress, which took place in Geneva on 18 to 20 October 2022, invited experts to help drive progress and address the global burden of cancer through the power of knowledge sharing and collective action.
On day one of the Congress, Tien Hoang Tran of the National Cancer Center Graduate School of Cancer Science and Policy in Korea shared a presentation called ‘Proton Pump Inhibitors Exposure and Risk of Cancers: A Meta Analysis of Cohort Studies’.
It included the results of a meta-analysis of cohort studies to calculate the pooled cancer risks among individuals exposed vs. not exposed to proton pump inhibitors. The analysis included 15 cohort studies with a combined 5.2 million individuals.
Evidence from multiple studies presented at the World Cancer Congress (WCC) in Switzerland suggests an association between long-term use of PPIs and a higher risk of developing gastric cancer..
Indeed, results showed a statistically significant increased risk for cancer among individuals exposed to proton pump inhibitors.
There were also significant associations noted between PPI use and gastric cancer as well as liver cancer. However, researchers observed no association with colon cancer. The investigators also reported significant associations between cancer risk and use of lansoprazole and omeprazole.